Assessment of L-Arginine supplementation on insulin resistanc, sugar and lipid profile

Assessment of L-Arginine supplementation on insulin resistanc, sugar and lipid profile in patients with type II diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012071010240N1

Enrollment

Registered

2014-09-24

Start date

2013-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: 3gr/d L-arginine for 3 months. Intervention 2: 6gr/d L-arginine for 3 months. Intervention 3: 3gr/d placebo for 3 months.

Treatment - Drugs

3gr/d L-arginine for 3 months

6gr/d L-arginine for 3 months

3gr/d placebo for 3 months

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Criteria for inclusion in the study: Suffering from diabetes type 2? Diabetes record between 4-10 years. Fasting glucose range of 160-400 mg/dl. Aged between 30 to 60. Criteria for exclusion from the study: Suffering from Renal, Liver; Parathyroid and GI Diseases. Pregnancy and lactation. Use of insulin; HbA1c<7mg/dl

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HbA1c. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;Insulin. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Insulin kit.;Fasting blood sugar. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Autoanalaizer.;HDL. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;LDL. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;TG. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;Cholesterol. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.	—

Measure

Time frame

HbA1c. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;Insulin. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Insulin kit.;Fasting blood sugar. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Autoanalaizer.;HDL. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;LDL. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;TG. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;Cholesterol. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.

—

Secondary

Measure	Time frame
Anthropometric indicators: weight, height, body mass index, waist circumference. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Tape and scale.;Insulin Resistance. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: HOMA index.;Insulin Sensitivity. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: HOMA2 calculator software.;Beta cell function. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: HOMA2 calculator software.	—

Measure

Time frame

Anthropometric indicators: weight, height, body mass index, waist circumference. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Tape and scale.;Insulin Resistance. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: HOMA index.;Insulin Sensitivity. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: HOMA2 calculator software.;Beta cell function. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: HOMA2 calculator software.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Asadi

Shahid Sadoughi University of Medical Sciences

asadis_744@yahoo.com+98 35 1624 0691

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026